Skip to main content

Table 1 Patient characteristics

From: Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan

Variable

Value

Age (years), median (IQR)

73 (64–78)

Sex, number (%)

 

Male

12 (67)

Female

6 (33)

ECOG PS, number (%)

 

0

14 (77.8)

1

2 (11.1)

2

1 (5.6)

3

1 (5.6)

MSKCC risk group*, number (%)

 

Favorable

10 (55.6)

Intermediate

5 (27.8)

Poor

3 (16.7)

Site of metastasis, number (%)

 

None

5 (27.8)

Lung

5 (27.8)

Lymph node

4 (22.2)

IVC thrombus

4 (22.2)

Bone

2 (11.1)

Liver

1 (5.6)

Prior to nephrectomy, number (%)

4 (22.2)

Follow-up period (months), median (IQR)

11.5 (5.1–17.4)

  1. * Risk groups are stratified in accordance with the Memorial Sloan-Kettering Cancer Center (MSKCC) criteria associated with shorter survival based on five risk factors: low Karnofsky performance status (<80%), high LDH (>1.5 times the upper limit of normal), low serum hemoglobin, high corrected serum calcium (>10 mg/dL), and interval of <1 year between initial diagnosis and axitinib treatment [3]
  2. ECOG PS, Eastern Cooperative Oncology Group performance status; IVC, inferior vena cava